Please assess the completion status of the following clinical trial:

Trial Title: Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: DEFINED_POPULATION
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patient aged \> 18 years~* Admitted to an ICU with an expected ICU length of stay \> 72 hours~* Severe renal insufficiency, defined by a calculated CrCl \< 30 mL/min/1.73m2~Exclusion Criteria:~* ICU admission for \> 2 weeks at time of screening~* ICU admission within 3 months of cardiac surgery or neurosurgery~* Active bleeding or at high risk for bleeding complications~* Thrombocytopenia (platelet count \< 75 x 10\^9/L) at time of screening~* Coagulopathy (International Normalized Ratio \[INR\] or activated partial thromboplastin time \[aPTT\] \> 2 times upper limit of normal) at time of screening~* Patient had an indwelling epidural catheter for epidural analgesia within the last 12 hours~* Receipt of \> 2 doses of LMWH (prophylactic- or therapeutic-dose) in the ICU~* Receiving or requiring therapeutic-dose anticoagulation (eg., deep vein thrombosis \[DVT\]) at time of screening~* Receiving dialysis that requires anticoagulation (eg., PRISMA, slow continuous ultrafiltration \[SCUF\]) at time of screening~* Weight \< 45 kg~* Woman who is pregnant or lactating~* Bilateral lower limb amputation~* Previous adverse reaction to heparin or LMWH (eg., allergy, heparin-induced thrombocytopenia \[HIT\])~* Contraindication to receiving blood products~* Life expectancy \< 14 days or receiving palliative care~* Prior enrolment in this study or enrolment in a concurrent related clinical trial~* Patient or surrogate decision-maker does not provide consent to participate in study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).